Aims

The objectives of the network in detail are:

N

Molecular diagnosis of all patients with lung cancer in the network for all genomic changes with the already stored or to be evaluated clinically and therapeutically relevant driver mutations

N

Implementation of a high-quality molecular testing with continuous method development towards an optimized multiplex-test, and continuous adaptation to the latest findings in basic genomic research

N

Establishment of a central database for comprehensive tracking of individual courses of disease after tumor diagnosis and continuous evaluation of molecular diagnostics and personalized therapy with regard to penetration in the width of care and outcome (survival, disease control, quality of life), now also in cooperation with health insurers; the possibility of independent data evaluation outside of clinical trials.

N

Consulting of the participating centers with regard to the interpretation of the collected findings and their relevance in particular regarding possible personalized treatment options

N

Provision of a comprehensive offer for personalized trials, in order to offer participation in a clinical trial to as many patients as possible who have detected therapeutically relevant mutations.

N

Expansion of the network to other tumor entities, e.g. gastrointestinal tumors, melanomas.

N

Establishment of additional highly-qualified diagnostic centers with access to an interdisciplinary treatment environment to promote coverage of tumor diagnostics in Germany.

Last update: 07. March 2016 , 11:26

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.
Share This